Immune checkpoint inhibitor — Competitive Intelligence Brief

Immune checkpoint inhibitor (Immune checkpoint inhibitor) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immune checkpoint inhibitor. Area: Oncology.

phase 3 Immune checkpoint inhibitor Oncology Small molecule

Target snapshot

Immune checkpoint inhibitor (Immune checkpoint inhibitor) — John L. Villano, MD, PhD. Immune checkpoint inhibitors block inhibitory signals on T cells, allowing the immune system to recognize and attack cancer cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Immune checkpoint inhibitor TARGET	Immune checkpoint inhibitor	John L. Villano, MD, PhD	phase 3	Immune checkpoint inhibitor
Cisplatin / Carboplatin，Gemcitabine，Cindilimab	Cisplatin / Carboplatin，Gemcitabine，Cindilimab	People's Hospital of Quzhou	marketed	Combination chemotherapy with immune checkpoint inhibitor	DNA (platinum agents, gemcitabine); PD-L1 (cindilimab)
Immune Checkpoint Inhibitors	Immune Checkpoint Inhibitors	The Central Hospital of Lishui City	marketed	Immune checkpoint inhibitor
Ipilimumab and nivolumab	Ipilimumab and nivolumab	Leiden University Medical Center	phase 3	Immune checkpoint inhibitor combination (CTLA-4 inhibitor + PD-1 inhibitor)	CTLA-4 and PD-1
JSKN003	JSKN003	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	phase 3	Bispecific antibody; immune checkpoint inhibitor
Investigational products administration	Investigational products administration	Assistance Publique - Hôpitaux de Paris	phase 3	Immune checkpoint inhibitor	PD-1/PD-L1
Praga formulation	Praga formulation	EMS	phase 3	Immune checkpoint inhibitor	PD-1/PD-L1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immune checkpoint inhibitor class)

1. Sun Pharma Advanced Research Company Limited · 2 drugs in this class
2. Brenda Cooper, MD · 1 drug in this class
3. Grace Therapeutics Inc. · 1 drug in this class
4. EMS · 1 drug in this class
5. GERCOR - Multidisciplinary Oncology Cooperative Group · 1 drug in this class
6. Glycotope GmbH · 1 drug in this class
7. Bristol-Myers Squibb · 1 drug in this class
8. HK inno.N Corporation · 1 drug in this class
9. Hanlim Pharm. Co., Ltd. · 1 drug in this class
10. Assistance Publique - Hôpitaux de Paris · 1 drug in this class